Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.43)
# 950
Out of 5,090 analysts
106
Total ratings
47.62%
Success rate
5.85%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $5.39 | +104.08% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $3.95 | +51.90% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $3.33 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $489.31 | +7.29% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $53.40 | +68.54% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $455.48 | +5.38% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $52.15 | +5.47% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $121.22 | -34.00% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $10.85 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $718.36 | +41.29% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $329.89 | +22.77% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $458.12 | -51.98% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $15.62 | -35.98% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.68 | +14.44% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $56.88 | +26.58% | 1 | Apr 13, 2023 |
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.39
Upside: +104.08%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $3.95
Upside: +51.90%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.33
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $489.31
Upside: +7.29%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $53.40
Upside: +68.54%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $455.48
Upside: +5.38%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $52.15
Upside: +5.47%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $121.22
Upside: -34.00%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $10.85
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $718.36
Upside: +41.29%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $329.89
Upside: +22.77%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $458.12
Upside: -51.98%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $15.62
Upside: -35.98%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.68
Upside: +14.44%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $56.88
Upside: +26.58%